טוען...

Continuation of epidermal growth factor receptor tyrosine kinase inhibitor treatment prolongs disease control in non-small-cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors

OBJECTIVES: Patients with non-small-cell lung cancer (NSCLC) develop acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) after tumor regression. No approved targeted therapies are currently available after initial EGFR TKI treatment. This study investigated...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Oncotarget
Main Authors: Chen, Qi, Quan, Qi, Ding, Lingyu, Hong, Xiangchan, Zhou, Ningning, Liang, Ying, Wu, Haiying
פורמט: Artigo
שפה:Inglês
יצא לאור: Impact Journals LLC 2015
נושאים:
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC4694802/
https://ncbi.nlm.nih.gov/pubmed/26172562
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!